The stocks of REPH have been given a rating of buy by close to six brokerages that have been working on the firm. According to reports, one of the equities analysts gave the stock a rating of sell, while one of them gave it a recommendation of the hold. Four of the stock analysts gave the company a rating of buy. Currently, the stock has a price objective of $15 which has been set by the analysts using the predictions for the year.
The Quarterly Earnings Of REPH
Also, Craig Hallum was one of the companies that covered the shares of this company. They gave the stocks of REPH a rating of buy, which was published in a research report.
The shares of this company traded at $2.85 last Monday. The market cap of the firm is $67.39 million, with a beta of 0.61, and a PE ratio that was close to 14.25. The year low of the company was around $1.49, with the year high being fixed at $19.21. The moving average of the company over a period of 50-days is $2.53, with the moving average of the company over a period of 200-days is $2.94.
The company previously released its results on the quarterly earnings on the 9th of November. The company had reported an EPS of $0.09 for the quarter, where they ended up beating the estimate set by analysts at $0.21. The company had generated a revenue of $19.29 million for the present quarter, which was more than the consensus estimate of $17.50 million.
REPH is an organization that is involved in the manufacturing and contractual development of drug products that are used orally. The company was previously called Recro Pharma I but now is simply called Recro Pharma, Inc.
